| Name | Title | Contact Details |
|---|
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
dofound is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
H2h Solutions, Inc is a Wixom, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Barbara Davis Ct Chldhd Diabts is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Headquartered in Las Vegas, Nevada, GPO Plus, Inc. (OTC: $GPOX) is a publicly traded global holding company of industry-specific Group Purchasing Organizations (GPO). The main holdings are HealthGPO, a Group Purchasing Organization for the Healthcare industry, and cbdGPO, a Group Purchasing Organization for the CBD and Hemp industry.